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Resistance of pathogenic organisms has 
become a worldwide problem with serious 
consequence on the treatment of infectious 
diseases. Emergence and dissemination of β-
lactam resistance in nosocomial 
Enterobacteriaceae, Pseudomonas 
aeruginosa and Acinetobacter baumanni have 
pose a serious problem worldwide, especially 
the increasing resistance to different 
ABSTRACT 
Background: The emergence of beta-lactam resistance in Pseudomonas 
aeruginosa is a major global challenge, particularly, the rise in the resistance to 3rd 
and 4th generation cephalosporins. Aim: This study was carried out to determine the 
resistance pattern of Pseudomonas aeruginosa to different generations of 
cephalosporins. Methods: A total number of one hundred clinical isolates of 
Pseudomonas aeruginosa were collected from June to November 2014 at University 
Teaching Hospital Ibadan, Oyo State. These were tested for their sensitivity to 
antibiotics by means of disc diffusion method using prepared antibiotics disc 
containing different µ of antibiotics; Cefotaxine (30µ), Cefaclor (30µ), Cefamandole 
(30µ), Cefixime (5µ), Cefepime (30µ), Cefpodoxime (30µ) and Ceftazidime (30µ). 
Results: Pseudomonas aeruginosa showed absolute resistance to all antibiotics 
used except Ceftazidime, and Cefepime which are third and fourth generation of 
cephalosporin respectively. Ceftazidime had minimal resistant of 21% and higher 
susceptibility rate of 76%, Cefepime had the highest susceptibility rate of 90% and 
minimal resistance of 6%. Cefotaxime and Cefpodoxime had minimal intermediate of 
1%, Ceftazidime of 3% and Cefepime of 4%. Conclusion: The result from this study 
provided more evidence that among third generation of cephalosporins used, some 
are more active than the other while fourth generation is still the most effective of all 
other generations. Knowledge on the distribution of cephalosporin-resistant 
organisms is of ultimate importance as a guide in empirical therapy, taking note of 
preventive strategies as well as control measures against the spread of resistant 
microorganisms. 
Key words: Cephalosporins, resistance, susceptibility, Pseudomonas aeruginosa, 
antibiotics, organism 
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generations of Cephalosporins.[1] Infections 
due to gram-negative organisms, 
Pseudomonas aeruginosa being the most 
common, continue to be one of the leading 
causes of health care-acquired infections as 
well as morbidity and mortality in the 
healthcare system.[2,3] Pseudomonas 
aeruginosa, a gram-negative bacterium, is 
found in healthcare-associated infections 
especially in patients who have been 
hospitalized more than a week and is reported 
in different outbreaks of infections such as 
pneumonia, bacteremia, urinary tract infection, 
and endocarditis, which are often complicated 
and potentially life-threatening.[4,5] Wound 
infections have been the leading reservoir for 
the bacterium as well as burn patients.[6] 
Cephalosporins are used to treat a wide 
variety of bacterial infections caused by 
Pseudomonas aeruginosa not limited to 
respiratory tract infections, otitis media, 
gonorrhoea, skin infections, urinary tract 
infections and sexually transmitted diseases.[7]  
According to Oladipo et al.,[2,3] Eyo et al.,[1] and 
Ramalingam et al.,[8] the fundamental 
mechanism of Pseudomonas aeruginosa 
resistance to cephalosporin involves the 
production of enzymes, extended spectrum β-
lactamases (ESBLs) that aids in the bacterium 
resistance, that is, bacterial resistance to beta-
lactam antibiotics is due to the enzymatic 
inactivation of antibiotics, that is, the 
production of enzyme β-lactamase which 
hydrolyses the β-lactam ring of the antibiotics 
rendering them inactive. Extensive use and 
misuse of antibiotics of the public alongside 
inappropriate practices of unskilled health 
workers and practitioners have led to the 
increasing resistance of nosocomial 
microorganisms.  
 
Different generations of cephalosporin, first, 
second, third and fourth generations, are 
broad spectrum antimicrobial agents with 
enhanced activity against both gram-positive 
and gram-negative organisms.[3] They have 
been assured successful in the treatment of 
severe and multi-drug resistant infections, 
however, increased prevalence of nosocomial 
strains of Pseudomonas aeruginosa resistance 
to cephalosporin among clinical isolates has 
been reported.[9] Knowledge on the distribution 
of cephalosporin-resistant organisms is 
important for guide in empirical therapy, taking 
note of preventive strategies as well as control 
measures against the spread of resistant 
microorganisms. This study therefore is 
designed to determine the antimicrobial 
susceptibility pattern of selected clinical 






This research was carried out in Ibadan, Oyo 
State, South Western part of Nigeria, in order 
to determine the resistance pattern of clinical 
isolates of Pseudomonas aeruginosa to 
different generations of cephalosporin among 
the patients at University Teaching Hospital 
Ibadan, Oyo state, Nigeria over a period of five 
months (June to November 2014).  
 
Bacterial isolates 
A total number of one hundred (100) clinical 
isolates of Pseudomonas aeruginosa from 
different clinical sites including burns, wounds 
and ear were used for this study. These 
samples were obtained from University 
Teaching Hospital Ibadan. 
 
Processing of samples 
Media were prepared according to the 
manufacturer’s instructions and sterilized at 
1210C for 15min at 15 lb pressure. The 




The susceptibility test was conducted using 
the Kirby- Bauer method of sensitivity 
determination.[2,3] Petri – dishes of Mueller 
Hinton agar were prepared according to the 
manufacturer’s instruction. 0.1ml of 
Pseudomonas aeruginosa equivalent to 0.5 
McFarland standard was seeded into each of 
the Petri-dishes containing Mueller-Hinton 
agar using sterile swabs.[2] These were 
allowed to stand for 45min to enable the 
inoculated organisms to pre-diffusion.[3] The 
antibiotics discs of Cefadroxil (30µg; Oxoid, 
UK), Cefotaxim (30µg; Oxoid, UK), 
Cefamandole (30µg; Oxoid, UK), Cefador 
(30µg; Oxoid, UK), Cefpodoxime (10µg; Oxoid, 
UK), Cefixime (5µg; Oxoid, UK) and Cefepime 
(30µg; Oxoid, UK) were aseptically placed on 
the surfaces of the sensitivity agar plates.[2,3] 
These were incubated aerobically for 18–24 
hours at 37ºC and the radial zone of inhibitions 
were taken.[2,3] The results were expressed as 
susceptible, intermediate or resistant 
according to criteria developed by Clinical 
Laboratory Standard Institute.[10,11] 
 
Statistical analysis  
Susceptibility rates were analyzed using 
ANOVA at significant level of P≤0.05. All 
interval estimates are 95% confidence 
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intervals. SPSS program for Windows (version 




Distribution of Pseudomonas aeruginosa 
from different sites 
Figure 1 shows the distribution of the clinical 
isolates of Pseudomonas aeruginosa from the 
different sites. Ear swab was 23, burns was 30 
while wound swabs was 47. 
 
Resistance pattern of Pseudomonas 
aeruginosa to different generations of 
Cephalosporin 
From table 1, out of 23 Pseudomonas 
aeruginosa isolated from ear swab, 17(73.9%) 
were susceptible to Ceftazidime while the 
remaining 6(26.1%) were resistant. 19(89.2%) 
of the isolates were susceptible to Cefepime 
while 2(8.9%) showed intermediate effect. All 
the isolates were resistant to Cefotaxime, 





Among 30 isolate obtained from burns, 
1(3.3%) showed intermediate effect to 
Cefotaxime and 29 (63.3%) were resistant. 
24(80%) of the isolate were susceptible to 
Ceftazidime, 1(3.3%) showed intermediate and 
the remaining 5(6.7%) were resistant to the 
antibiotic. 29(96%) of the isolate were 
susceptible to Cefepime and the remaining 
1(3.3%) was resistant. All the isolate from this 
site were resistant to Cefamandole, Cefador, 
Cefpodoxime and Cefixime. 
 
From the 47 isolates from wound, 1(2.1%) 
showed intermediate effect to Cefpodoxime 
while the remaining 46(97.9%) were resistant. 
35(74.5%) were susceptible to ceftazidime, 
2(4.3%) showed intermediate effect and the 
remaining 10(21.3%) were resistant. 
42(89.4%) of the isolate were susceptible to 
Cefepime, 2(4.3%) showed intermediate effect 
and 3(6.4%) were resistant. All the 
Pseudomonas aeruginosa isolates from this 
site were resistant to Cefotaxime, 
Cefamandole, Cefador and Cefixime. 
 
Summarily, the susceptibility rate of 
Pseudomonas aeruginosa to Cefotaxime was 
0% sensitive, 1% intermediate and 99.0% 
resistant. Cefamandole was 0% sensitive, 0% 
intermediate and 100% resistant. Cefador was 
0% sensitive, 0% intermediate and 100% 
resistant. Cefpodoxime was 0% sensitive, 1% 
intermediate and 99.0% resistant. Cefixime 
was 0% sensitive, 0% intermediate and 100% 
resistant. Ceftazidime was 76% sensitive, 
3.0% intermediate and 21% resistant. 
Cefepime was 90% sensitive, 4% intermediate 
and 6.0% resistant. The overall resistant 
pattern of Pseudomonas aeruginosa to 
different generations of cephalosporin was 
23% sensitive, 1.3% intermediate and 75.0% 
resistant. 
 
ANOVA for resistant Pseudomonas 
aeruginosa isolates from different sites to 
cephalosporin 
From table 2, no significant difference was 
recorded in the mean effect of the second 
(Cefotaxime, Cefamandole and Cefador) and 
third (Cefpodoxime and cefixime) generations 
on the ear swab isolates of Pseudomonas 
aeruginosa. However, significant difference 
was recorded on Ceftazidime and Cefepime 
with mean values of 1.52 and 1.26 
respectively. 
 
From the isolates got from burn a slight 
difference was recorded on Cefotaxime with a 
mean value of 2.97. No significant difference 
was recorded on Cefamandole and Cefador 
(second generation) as well as Cefpodoxime 
and Cefixime (third generation). There was 
significant difference in the mean effect of 
Ceftazidime and Cefepime (third and fourth 
generations) with mean values of 1.37 and 
1.07, respectively.  
 
From the isolates on wound swabs, no 
significant difference was recorded in the 
mean effect of the second generation 
cephalosporin. On the third generation, 
Cefpodoxime, Cefixime and Ceftazidime 
showed significant differences with mean 
values of 2.96 and 15.67 and 9.94, 
respectively. Cefepime, a fourth generation, 
also showed a significant difference with a 
mean value of 1.17. 
Oladipo et al.: Cephalosporin resistance among clinical isolates of Pseudomonas aeruginosa 





Table 1: Susceptibility pattern of pseudomonas aeruginosa to different generations of  




Second Generation  Third Generation  Fourth 
Generation 
Total 
CTX MA CEC CPD CFM CAZ FEP  
S I R S I R S I R S I R S I R S I R S I R S I R 
Ear swab 0 0 23 0 0 23 0 0 23 0 0 23 0 0 23 17 0 6 19 2 2 36 2 123 
Burns 0 1 29 0 0 30 0 0 30 0 0 30 0 0 30 24 1 5 29 0 1 53 2 155 
Wound 
swab  
0 0 47 0 0 47 0 0 47 0 1 46 0 0 47 35 2 10 42 2 3 77 5 247 
Total  0 1 99 0 0 100 0 0 100 0 1 99 0 0 100 76 3 21 90 4 6 1669 525 
Susceptibility 
(% ) 
0 1 99 0 0 100 0 0 100 0 1 99 0 0 100 76 3 21 90 94 6 23.71.3 75.0 
CTX = Cefotaxime, MA = Cefamandole, CEC = Cefador, CPD= Cefpodoxime, CFM = Cefixime,  
FEP = Cefepime. S = Sensitive, I = Intermediate, R = Resistant. CLSI criteria;  
For Cefotaxime, S is ≥ 23, I is ≤ 15-22 and R is ≤ 14, Cefamandole, S is ≥ 18, I is ≤ 15-17, and R is ≤ 14;  
for Cefadroxil, S is ≥ 18, I is ≤ 15-17, and R is ≤ 14; for Cefpodoxime, S is ≥ 21, I is ≤ 18-20 and R is ≤17,  
for Cefador, S is ≥ 18, I is ≤ 15-17 and R is ≤ 14; for  Cefexime, S is ≥ 20, I is ≤ 17-19, and R is ≤ 16,  
for Cefepime, S is ≥ 18, I is ≤ 15-17 and R is ≤ 14. 
 
Table 2: ANOVA for the resistance of Pseudomonas aeruginosa isolated from  
different sites to different generations of cephalosporin  
 
Isolate site Generation of Cephalosporins 
Second Third Fourth 
   
CTX MA CEC CPD CFM CAZ FEP 
Ear swab 3.00±0.0
a 
3.00±0.00a 3.00±0.00a 3.00±0.00a 3.00±0.00a 1.52±0.00a 1.26±0.00a 
Burns 2.97±0.00
a 
3.00±0.00a 3.00±0.00a 3.00±0.00a 3.00±0.00a 1.37±0.00a 1.07±0.00a 
Wound swab 3.00±0.00
a 
3.00±0.00a 3.00±0.00a 2.96±0.00a 3.00±0.00a 15.67±0.00a 1.17±0.00a 
P=0.05; value=mean±standard mean error; values followed by the same alphabet are not 
significantly different according to Ducan’s multiple range test. 
CTX=Cefotaxime, MA=Cefamandole, CEC=Cefador, CPD= Cefpodoxime,  
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Cephalosporin is one of the most widely used 
antibiotics in the treatment of both gram-
positive and gram-negative organisms.[2,3] This 
study was conducted to evaluate the 
resistance activity of Pseudomonas 
aeruginosa obtained from clinical specimens 
against different generations of cephalosporin. 
Invitro activities of cephalosporins 
(Cefamandole, Cefaclor, Cefpodoxime, 
Cefixime, Ceftazidime and Cefepime) were 
tested using 100 isolates of Pseudomonas 
aeruginosa. This bacteria has been reported to 
develop resistance to antimicrobial agents 
both through accumulation of resistance genes 
on extra chromosomal genetic elements as 
well as through mutational processes.[12,13,14,8] 
According to previous studies, emerging 
resistant strains of Pseudomonas aeruginosa 
are potentially linked to injudicious use of 
drugs, failure to complete therapeutic 
regimens and variation in the doses 
administered leading to ineffective empirical 
therapy which in turn leads to the appearance 
of even more resistant strains of the 
bacterium.[5,9] 
 
Pseudomonas aeruginosa isolates from 
different sites; wounds (n=47), ear swabs 
(n=30) and burns (n=23) were found to be 
similar to those obtained by Masaad[15] and 
Rajat et al.[16] The majority of the isolates (n = 
47) were recovered from infected wounds 
which agrees with the reports of Masaad,[15] 
Anuradha et al.,[17] Oladipo et al.,[2,5] Eyo et 
al.,[1] Zafer et al.,[7] and Shah et al.,.[9] It has 
been observed that Pseudomonas aeruginosa 
is more associated with wound infections when 
compared with other clinical sites. 
 
In this study, Pseudomonas aeruginosa had 
high resistance to Cefotaxime (99%), 
Cefamandole (100%) and Cefaclor (100%) 
which are second generation cephalosporin. 
This study is comparable with a study by Smith 
et al.,[18] and Tassios et al.,[19] with 96% and 
92% multidrug resistant isolates respectively. 
The 99% resistance of Pseudomonas 
aeruginosa to Cefotaxime does not agree with 
the reports of Manchi et al.,[14] who recorded a 
resistance of 45% and 55% sensitivity; Anjum 
et al.,[20] who recorded a resistance of 73%, 
18% intermediate and 9% sensitivity and 
Prakash et al.,[4] who recorded a resistance of 
60.47% this could be as a result of access and 
usage of antibiotics in this community. 
However, the intermediate activity against 
Pseudomonas aeruginosa agrees with the 
comparative study of Ahmad et al.[21] 
Also, the resistance (6.0%) and sensitivity 
(90%) of Pseudomonas aeruginosa to 
Cefepime in this study does not correlate with 
the study of Manchi et al.,[14] who recorded 
equal sensitivity and resistance of 50%. This 
suggests that the organism have developed 
resistance with the passage of time as 
explained by Chaudhary and Payasi.[22] This 
statement explains the disagreement between 
this present study and the reports of Manchi et 
al.,[14] and Shah et al.,[9] about the resistance 
of Pseudomonas aeruginosa to Ceftazidime 
which is 21% to 45% and 45.5% respectively.  
 
In a study conducted by Jazani et al.[23] on 
antibiotic resistance of Cefepime, it has shown 
75.4% resistance, 22.4% intermediate 
resistance and 2.1% sensitivity. However, in 
this present study, the observations were 
comparatively less similar as 6.0% resistance, 
4.0% intermediate resistance and 90% 
sensitivity was seen. This result also disagrees 
with the reports of Prakash et al.[4] who 
recorded a resistance of 65.26%, Oladipo et 
al.,[2] who reported a 34.38% sensitivity, 6.25% 
intermediate and 59.37% resistance as well as 
Shah et al.,[9] who gave a 63.9% resistance. 
This suggests that the organism have 
developed resistance with the passage of time 
as well as inappropriate use of the antibiotics. 
 
Of the tested isolates of Pseudomonas 
aeruginosa against third generation 
cephalosporin, Cefpodoxime and Cefixime 
showed high resistance of 99% and 100% 
respectively, Ceftazidime showed significant 
sensitivity with 76%. This result confirmed the 
findings of Masaad,[15] Kechrid and Hassen,[24] 
and Ramalingam et al.[8] who found the activity 
of third generation cephalosporin on 
Pseudomonas aeruginosa to be 97%. The 
resistance to second generation cephalosporin 
could be as a result of drug abuse since they 
are cheaper as compared to the third and 
fourth generations. According to Manchi et 
al.,[14] third and fourth generation 
cephalosporins have better sensitivity when 
compared to first and second generation as 
shown from the study carried out in India 
which agrees with this study. The result also 
revealed a high sensitivity to Cefepime, a 
fourth generation, with 90%. This agrees with 
the result obtained from the studies of 
Pichichero[25] and Eyo et al.,[1] that newer 
generations of cephalosporin have significant 
antimicrobial properties than the preceding 
generations. From the result obtained from this 
study, Cefepime is considered as empirical 
therapy of first choice for the treatment of 
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infections caused by Pseudomonas 
aeruginosa as less resistance was shown. 
 
Analysis from this study showed that a 
significant difference was observed in the 
mean effect of fourth generation cephalosporin 
(Cefepime) on Pseudomonas aeruginosa on 
the isolates from ear swab, burn and wound, 
with mean values of 1.26, 1.07 and 1.17 
respectively. This may be due to the ability of 
Pseudomonas aeruginosa obtained from 
different sites to produce beta-lactamase that 
reduces the activity of cephalosporin. This 
result agrees with the report of Pichichero.[25] 
However, it disagrees with the report of 
Oladipo et al.,[2,3] with mean effect of the 
antibiotics on the isolate from ear swab and 
wound to be 2.32 and 2.45 respectively. No 
significant difference was observed in the 
mean effects of both second and third 
generations cephalosporin used on the clinical 
isolates of Pseudomonas aeruginosa. This 
may be due to mutation in the genetic makeup 




Antibiotic resistance is threatening the 
accomplishment of health services and it has 
since been considered as a universal risk. 
Third and fourth generation cephalosporins 
could still be used if found appropriate based 
on culture and sensitivity despite high 
incidence of resistance of Pseudomonas 
aeruginosa to all the different generation of 
cephalosporins; however, indiscriminate use 
may lead to increased resistance. Diagnostic 
procedures should not only aim at identifying 
the pathogen but also determining its 
susceptibility to antibiotics before prescription. 
Furthermore, there should be a continued 
search for new diagnostic methods due to the 
complexity of multiresistant phenotypes and 
emergence of new resistance mechanisms. 
Also, essential prophylactic measures such as 
proper hygiene, reducing of the risk factors of 
nosocomial infections and evidence-based 
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